Abstract A 64-year-old woman admitted to our hospital with the chief complaint of swallowing obstruction was diagnosed as relapsed small-cell carcinoma of the esophagus. Complete remission (CR) was observed after six cycles of irinotecan plus cisplatin therapy. According to the results of a next-generation sequencing analysis of the tumor specimen, anlotinib (12 mg PO q3w) was recommended. After 1 month of anlotinib treatment, the tumor decreased significantly according to computed tomography scan and gastroscopy. However, the disease progressed after 2 months of therapy. A gene analysis of the new puncture sample showed microsatellite instability and a high tumor mutation burden. Immunohistochemistry indicated positive programmed death ligand-1 expression (>1%). Because of these results, the patient was treated with anlotinib (12 mg PO q3w) in combination with toripalimab (240 mg IV drip q3w). After 3 months of therapy, CR was achieved, although progression-free survival had not been reached at the time of publication. Keywords: anlotinib, toripalimab, NGS, cell esophagus carcinoma Introduction Small-cell lung carcinoma (SCLC) has historically one of the highest malignancy rates of all tumor types.[28]^1 Anlotinib combined with PD-1 therapy has been approved in Chinese Clinical Guidelines for SCLC. By comparison, small-cell carcinoma of the esophagus (SCCE), which accounts for only 0.5%–2.8% of all esophageal malignancies,is a particularly rare tumor characterized by high malignancy, early metastasis, and poor prognosis,[29]^2 without classical therapy guidelines. Because of the low incidence of SCCE, the results of large-scale randomized controlled studies are obscure.[30]^3–10 Therefore, the optimal, standard treatment for limited-stage SCCE has not been established. Herein, we report a case of chemotherapy resistance in a patient who showed achieved complete remission (CR) to therapy with anlotinib, which is a tyrosine kinase-targeted agent, combined with toripalimab, which is an immune checkpoint inhibitor (ICI). This case mirrored the same pathological type in different cancers that were treated with the same therapy and achieved a good prognosis,[31]^11 thus providing a practical basis for “treating different diseases with the same therapy.” Method Patient A 64-year-old woman was diagnosed with locally advanced SCCE 4 years prior. After four cycles of combination chemotherapy of irinotecan (100 mg, days 1 and 8) and cisplatin (50 mg, days 1 and 8), CR was achieved. After 2.5 years, the patient returned to our hospital for the sensation of swallowing obstruction. The patient was diabetic, but there was no history of hypertension or cardiovascular disease. Furthermore, no swelling of the superficial lymph nodes was detected by physical examination. Next-Generation Sequencing-Based Assay Tumor DNA was extracted from formalin-fixed paraffin-embedded (FFPE) samples using QIAamp DNA FFPE Tissue Kit and Qiagen’s DNEasy Blood and Tissue Extraction Kit (Qiagen, Germany), respectively, according to the manufacturer’s instructions. Genomic DNA from peripheral blood was purified using the QIAamp DNA Blood Mini Kit (Qiagen). All FFPE tissue samples were reviewed by a qualified pathologist to ensure >70% tumor content. We performed next-generation sequencing (NGS) using OncoScreen Plus Kit (Burning Rock Biotech, Guangzhou, China), which is a panel consisting of 520 cancer-related genes spanning 1.64 Mb of the human genome in the NextSeq platform (Illumina, San Diego, CA, USA) ([32]Table 1). Table 1. NGS Results of Gastroscopy Puncture Samples Before and After Anlotinib Therapy Gene Before Alotinib Therapy After Alotinib Therapy Base Amino Acid Frequency Base Amino Acid Frequency BRCA2 c.8695C>T p.[Q2899*] 2.01% – – – RB1 c.1510C>T p.Gln504* 63.83% c.1510C>T p.Gln504* 80.42% TP53 c.1024C>T c.833C>A p.Arg342* p.Pro278His 35.19% 36.09% c.1024C>T c.833C>A p.Arg342* p.Pro278His 48.93% 42.67% ATRX c.2658_2659dup p.Thr887fs 25.34% c.2658_2659dup p.Thr887fs 25.89% KMT2A c.5419C>G p.[Q1807E] 39.36% – – – PIK3CA – – – Amplification 3q26.32 CN=4.45 PIK3CB c.1275T>A p.[Y425*] 21.84% – – – EP300 c.4228A>T p.Arg1410Trp 33.15% c.4228A>T Amplification p.Arg1410Trp 22q13.2 81.48% CN=6.78 TNFRSF8 c.443T>C p.[V148A] 17.28% – – – TNFAIP3 – – – c.1323del p.Ala442fs 34.34% CTNNB1 c.78G>T p.Gln26His 60.69% – – – CSF1R c.1151G>A p.Arg384Lys 42.21% c.1151G>A p.Arg384Lys 60.69% FAT1 – – – c.5515G>T p.Glu1839* 90.49% PTK2 – – – Amplification 8q24.3 CN=6.02 SOX2 – – – Amplification 3q26.33 CN=5.87 MYC – – – Amplification 8q24.21 CN=5.26 [33]Open in a new tab Abbreviations: NGS, next-generation sequencing (OncoScreen Pluspanel, Nextseq); RB1, RB transcriptional corepressor 1; CTNNB1, catenin beta-1; PI3K, phosphatidylinositol 3-kinases; TNFAIP3, tumor necrosis factor, alpha-induced protein 3; MYC, myelocytomatosis oncogene. Functional and Pathway Enrichment Analysis The Gene Ontology (GO) database ([34]http://www.geneontology.org) includes three main categories: biological process, cellular component, and molecular function. The Kyoto Encyclopedia of Genes and Genomes database (KEGG; [35]http://www.genome.ad.jp/kegg) collects genomic, chemical, and systematic functional information. The Cluster Profiler package implements methods for analyzing and visualizing the functional profiles of genes and gene clusters. In this study, GO terms and KEGG pathways were analyzed using the Cluster Profiler package with an enrichment threshold of P < 0.05. Results Histopathologic examination of gastroscopy biopsy specimens indicated relapsed SCCE ([36]Figures 1A and [37]3A). Immunohistochemistry results showed positive staining of high molecular weight cytokeratin 56 ([38]Figure 1B), alpha-synuclein ([39]Figure 1C), and Ki-67 (80%) ([40]Figure 1D). We performed NGS testing but did not find any meaningful mutations ([41]Table 1). According to these results, irinotecan (100 mg, days 1 and 8) and cisplatin (50 mg, days 1 and 8) chemotherapy was administered for another six cycles. However, computed tomography (CT) scan and gastroscopy indicated disease progression ([42]Figure 2A) after intraperitoneal(IP)chemotherapy. The following NGS examination of the gastroscopy biopsy specimens indicated a significant increase in the mutation rates of BRCA2, RB1, TP53, ATRX, KMT2A, PIK3CB, EP300, TNFRSF8, CTNNB1, and CSF1R. Anlotinib, which is an oral tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptor, has been approved as a third-line recommended therapy in the 2020 Chinese Society of Clinical Oncology (CSCO) guideline for SCLC. Considering the similar histopathology of the patient,[43]^12^,[44]^13 anlotinib was suggested to the patient (12 mg PO q3w). After 1 month, both the CT scan and gastroscopy therapy showed that the esophageal wall had returned to normal ([45]Figures 2B and [46]3B), with limited side effects (normal levels of transaminase, hypothyroidism, and grade I hyperlipidemia). After 3 months, the esophageal wall thickened again ([47]Figures 2C and [48]3C). The third NGS assay showed significant mutation changes: The mutations BRCA2, KMT2A, PIK3CB, TNFRSF8, and CTNNB1 disappeared, whereas the mutations TNFAIP3 and FAT1 appeared. The mutation rates of RB1, TP53, EP300, and CTNNB1 significantly increased, whereas those of CSF1R decreased. A copy number amplification was observed in PIK3CA, PTK2, SOX2, and MYC. A high tumor mutation burden (TMB) (57.1 mutations/Mb) was observed, and immunohistochemistry detected a positive programmed death ligand-1 expression rate (PD-L1 > 1%) ([49]Figure 4). Based on these results, this patient was an ideal candidate for treatment with ICIs.[50]^14^,[51]^15 For economic reasons, toripalimab (240 mg IV drips q3W) was chosen as the ICI. Improvement of her physical condition was observed after one cycle of combined treatment, and the sensation of swallowing obstruction disappeared. After 3 months of therapy, the clinical response was characterized as CR ([52]Figures 2D and [53]3D). Until the time of publication, the patient has remained in CR, and the progression-free survival (PFS) has not yet been reached after a follow-up at13 months (PFS > 13 months). The patient signed informed consent forms, which allowed for the publication of the relevant clinical and imaging data from her case. Figure 1. [54]Figure 1 [55]Open in a new tab (A) Hematoxylin and eosin staining of biopsy specimens indicated SCCE (200×). (B) IHC showed positive staining of high molecular weight cytokeratin 56 with diffusion (200×). (C) IHC showed positive staining of alpha-synuclein (200×) Syn (+), and (D) Ki-67 (200×) 80% positive. Figure 3. [56]Figure 3 [57]Open in a new tab Gastroscopy during therapy. (A) SCCE relapse after six courses of IP chemotherapy. (B) Significant esophageal wall shrinkage after 1 month of anlotinib monotherapy.(C) Esophageal wall re-thickening following 3 months of anlotinib monotherapy. (D) Lugo’s iodine staining of the esophageal wall 3 months after treatment with anlotinib in combination with toripalimab. Figure 2. [58]Figure 2 [59]Open in a new tab Chest CT scans during therapy. (A) SCCE relapsed after six courses of IP chemotherapy. (B) Esophageal wall shrinkage after 1 month of anlotinib monotherapy. (C) Esophageal wall re-thickening after 3 months of anlotinib monotherapy. (D) After 3 months of treatment with anlotinib in combination with toripalimab. Figure 4. [60]Figure 4 [61]Open in a new tab (A and B) IHC of PD-L1-positive expression in tumor biopsy specimens (brown). (A) Before anlotinib therapy, TPS < 1%; (B) after anlotinib therapy, TPS ≥1%. The GO and KEGG enrichment analyses of differentially expressed genes (DEGs) before and after anlotinib therapy were conducted using the Cluster Profiler package to further understand the function and mechanism of the therapy ([62]Figure 5). In the GO analysis, DEGs mainly indicate leukocyte migration, extracellular matrix organization, extracellular structure organization, and cell−substrate adhesion (10/10, P < 0.005). According to the KEGG analysis, according to the GO analysis, the significant enrichment before therapy with anlotinib combined with toripalimab was the focus of focal adhesion kinase (FAK) (7/10, P < 0.005). Figure 5. [63]Figure 5 [64]Open in a new tab (A) Enrichment of the molecular function. (B) Enrichment of the cellular component (blue represents low aggregation; red represents high aggregation, and the larger the ball is, the more mutation genes it contains). Discussion In 2019, anlotinib was approved by the CSCO as a third-line treatment option for esophageal squamous cell carcinoma. In 2020, anlotinib was also approved to treat SCLC. However, cases of SCCE treatment with anlotinib have not been reported yet. After two lines of treatment, the patient refused further chemotherapy treatment. Additionally, NGS testing did not indicate any typical mutations. However, NGS showed a high RB1 mutation rate accompanied by TP53 mutation, which is common in advanced SCCE,[65]^16 and it indicates tumor growth due to chemotherapy resistance.[66]^17 Additionally, a high mutation of CTNNB1,[67]^18^,[68]^19 which plays a critical role in tumor metastasis, might lead to innate primary resistance to ICIs, meaning immunotherapy may be unsuitable to use at that time. The high mutations in TP53 and TNFRSF8[69]^20^,[70]^21 indicated that anlotinib therapy may be beneficial. According to both the cancer type and pathological type, anlotinib, as a novel multi-target tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling, was heavily recommended and chosen as the next line of therapy. To the best of our knowledge, this is the first report about the successful use of anlotinib for advanced SCCE, which is characterized by the efficacy of CRand3 months of PFS. Interestingly, after anlotinib therapy, NGS showed changes that provided important information for guiding the next line of treatment. After anlotinib therapy, the KMT2A mutation disappeared and PTK2 amplified, which indicated an inhibition of metastasis and was interpreted as the patients benefiting from anlotinib therapy.[71]^22 As the mutation rate of CSF1R increased, the CTNNB1 mutation disappeared and MYC was amplified,[72]^23 which likely indicated a resistance to anlotinib. A high TMB (57.1 mutations/Mb) indicated a potential benefit from ICI. According to the results mentioned above, the patient had a PD-L1 expression of more than 1%, so anlotinib combined with toripalimab was selected as the next line of treatment. According to the results of the GO and KEGG enrichment analyses of DEGs before and after anlotinib therapy, we deemed the FAK signal may be the main target for providing this patient with individualized treatment. FAK is known to be over expressed and activated in SCLC.[73]^24^,[74]^25 FAK is critical in cancer development and progression because of its influence on multiple biological processes, such as crosstalk between the cell and its microenvironment, cell growth, survival, adhesion, spreading, migration, invasion, angiogenesis, DNA damage repair, radio resistance, and regulation of cancer stem cells. It has been reported that the over expression of FAK in vascular endothelial cells promotes angiogenesis, and the vascular endothelial growth factor inhibitor usually inhibits FAK. Since FAK inhibition could decrease vascular permeability and tumor vasculature, as well as prevent tumor growth, metastasis, and immunosuppressive tumor infiltration by cells, especially T regulatory cells, a clinical trial evaluating the association of FAK (VS6063) and PD-1 (pembrolizumab)inhibitors is ongoing. The results of the clinical trial may provide more evidence for the combination of antiangiogenic therapy combined with PD-1 in malignant tumors. At the time of publication, the patient has remained in CR, although PFS has not yet been reached after a 13 month follow-up (PFS > 13 months). The present case study revealed an outcome of CR that is characterized by imaging examinations after 3 months of treatment, as well as good tolerance without significant adverse reactions. Our clinical data suggest that the combined treatment of anlotinib and toripalimab is a viable option for advanced SCCE that is resistant to chemotherapy. To the best of our knowledge, this is the first report of the successful use of anlotinib in combination with toripalimab for the treatment of advanced SCCE. To verify the efficacy and safety of this combination therapy, additional clinical trials with a larger sample size are needed. Additionally, the mechanism of the immunomodulatory effects of anti-angiogenic drugs should be studied further. Acknowledgment